New NHS gene therapy treatment Luxturna approved for vision loss – Who will this biotechnology help?

Biotechnology triumphs as the NHS approves the new gene therapy treatment Luxturna (voretigene neparvovec) for the treatment of Leber's congenital amaurosis (LCA) and the first vision loss patients are undergoing treatment to fix the faulty RPE65 gene. In this video, optometrist Martin Oguzie will walk you through some of the relevant news articles to help you get to the heart of this news and this new treatment Luxturna made by Novartis.

Don't forget to *subscribe* for more videos like this.

Resource Links:

• BBC initial coverage https://www.bbc.co.uk/news/health-49565740
• NHS England begins eye gene therapy https://www.england.nhs.uk/2020/02/first-patients-begin-gene-therapy-treatment-for-blindness/
• NICE approval info https://www.nice.org.uk/guidance/hst11/chapter/1-Recommendations
• Retina UK – Stem cell therapy for sight loss https://retinauk.org.uk/research/approaches-to-treatment/stem-cells/
• Novartis pdf on how Luxtrna (Voretigene Neparvovec) works https://novartis.gcs-web.com/static-files/6db84d3d-2f16-4b15-a91b-591596d14cf8
• RPE65 protein Wikipedia https://en.wikipedia.org/wiki/RPE65
• Retina UK - Stem Cells Info https://retinauk.org.uk/research/approaches-to-treatment/stem-cells/
• Luxturna website https://luxturna.com/

About this video:
We will have a look brief look at the work done by ophthalmology and ophthalmologist medical research teams to get to this biotechnology derived treatment to market. Luxturna (also known as Voretigene Neparvovec) is made by Novartis and has been approved by NICE and UK NHS for the treatment of vision loss due to a rare genetic eye disorder called Leber's congenital amaurosis (LCA). This video explores how this treatment works, who it is for and what it means for treating other eye and retinal conditions ranging from retinitis pigmentosa, AMD (age-related macular degeneration), amblyopia, and so on. The science is exciting and we explore some of that, particularly the role of RPE65 and how Luxturna is designed to replace the RPE65 faulty gene. This work is indeed exciting for medical research and is a great stop-gap and supplement to the work being done on stem cell research for retinal eye diseases.

------------------------------------------------------------------------

**Medical Disclaimer**
This channel contains general medical information.
The medical information is not advice and should not be treated as such.

The medical information on our website is provided without any representations or warranties, express or implied.
You must not rely on the information on our website as an alternative to medical advice from your doctor eye care professional provider.
If you have any specific questions about any eye care and medical matter, you should consult your doctor or eye care professional provider.
If you think you may be suffering from any medical condition, you should seek immediate medical attention.
You should never delay seeking medical advice, disregard medical advice or discontinue medical treatment because of information on this channel.
Any assistance you may receive from this channel does not constitute specific advice and accordingly should not be relied upon without further independent confirmation.
#Luxturna #GeneTherapy #biotechnology

*Some videos on this channel may from time to time contain referral links that attract small commissions (at no expense to you) that help the channel.

Видео New NHS gene therapy treatment Luxturna approved for vision loss – Who will this biotechnology help? канала Martin's Eye Tips